Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 707
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Shengjie Tang, Chao Qin, Haiyang Hu, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 320-320
Open Access | Times Cited: 128
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 96
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 557-565
Closed Access | Times Cited: 80
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 55
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
Maen Abdelrahim, Abdullah Esmail, Godsfavour Umoru, et al.
Current Oncology (2022) Vol. 29, Iss. 6, pp. 4267-4273
Open Access | Times Cited: 45
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Yue Chen, Haoyue Hu, Xianglei Yuan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 44
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Richard J. Sové, Babita K. Verma, Hanwen Wang, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 11, pp. e005414-e005414
Open Access | Times Cited: 34
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review
Santhasiri Orrapin, Sasimol Udomruk, Worakitti Lapisatepun, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3373-3373
Open Access | Times Cited: 31
The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
Lilong Zhang, Chen Chen, Dongqi Chai, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 31
Next-generation cancer vaccines and emerging immunotherapy combinations
Anne Brandenburg, Annkristin Heine, Peter Brossart
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 749-769
Closed Access | Times Cited: 5
Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
Alessandro Rizzo
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3912-3912
Open Access | Times Cited: 27
Tremelimumab and Durvalumab in the Treatment of Unresectable, Advanced Hepatocellular Carcinoma
Tiago Biachi De Castria, Danny N. Khalil, James J. Harding, et al.
Future Oncology (2022) Vol. 18, Iss. 33, pp. 3769-3782
Closed Access | Times Cited: 26
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6664-6664
Open Access | Times Cited: 22
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma
Sumit Siddharth, Panjamurthy Kuppusamy, Qitong Wu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8083-8083
Open Access | Times Cited: 22
Artificial intelligence applications to genomic data in cancer research: a review of recent trends and emerging areas
Maria Frasca, Davide La Torre, Marco Repetto, et al.
Discover Analytics (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 4
Gut microbiome and tumor immunotherapy
Mohini Vig, Shweta Dubey
International review of cell and molecular biology (2025)
Closed Access
Predictive Value of 18F‐FDG PET/CT in LA‐HNSCC Patients Undergoing Neoadjuvant Chemoimmunotherapy: A Prospective Study
Rong Huang, Xiaoxu Lü, Xueming Sun, et al.
Oral Diseases (2025)
Closed Access
The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity
Stavros P. Papadakos, Nikolaos Dedes, Elias Kouroumalis, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3150-3150
Open Access | Times Cited: 19
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
Qingqing Xie, Pengfei Zhang, Yuanyuan Wang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 19
Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations
Adam Hatzidakis, Lukáš Müller, Μiltiadis Krokidis, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2469-2469
Open Access | Times Cited: 16
Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma
Linping Xu, Hui Yang, Meimei Yan, et al.
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 6, pp. 2065-2083
Open Access | Times Cited: 16
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Xing Wang, Zi-yun Qiao, Beatrice Aramini, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 3, pp. 661-675
Closed Access | Times Cited: 10
CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors
Zhe Huang, Ping Zhou, Shan Shan Li, et al.
Cancer Imaging (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top